Abstract: Objective To evaluate the effects of exenatide on the plasma glucose, liver fat content and serum chemerin in type 2 diabetic(T2DM)combined with non-alcoholic fatty liver disease(NAFLD)patients. Methods Sixty patients with T2DM and NAFLD were randomly divided into exenatide group(n=30)and control group(n=30). Exenatide group was treated by exenatide(10 μg subcutaneous injection one hour before breakfast and dinner), and the control group was treated by insulin glargine(the starting dose was 0.2 U/kg or 6-10 U)for 12 weeks. The changes of body weight(BW), body mass index(BMI), fasting plasma glucose(FPG), glycosylated hemoglobin(HbA1c), blood lipid(including TG, TC, HDL and LDL), insulin resistance index(HOMA-IR), liver enzyme index(including ALT and AST)and serum chemerin levels were measured, and the change of liver fat content was quantitated by ultrasound. Results Treated for 12 weeks, the levels of BW, BMI, WHR, HbA1c, FPG, TG, 2hPG, ALT, AST in exenatide group were significantly declined(P<0.05, P<0.01), the levels of FINS, HOMA-IR, chemerin and LFC decresed(P<0.01); the levels of HbA1c and FPG decresed in control group(P<0.01). Correlation analysis showed that BMI, TG, HOMA-IR and chemerin were associated with LFC; the decrease of TG and HOMA-IR were 山 东 大 学 学 报 (医 学 版)54卷11期 -于宁,等.艾塞那肽对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪含量及血清chemerin水平的影响 \=-independently impacting factors for LFC by multiple stepwise regression analysis(β=1.614, 1.360, P<0.05). Conclusion Exenatide can improve the glucolipid metabolism and liver function, and reduce BW, LFC and serum chemerin levels, which may be the effect drugs for the treatment of T2DM combined with NAFLD.

Key words: Liver fat contents, Exenatide, Type 2 diabetes mellitus, Ultrasound, Chemerin